Lipopolysaccharide

PreclinicalSmall molecule

Boehringer Ingelheim

Lipopolysaccharide is one of 60 small molecule programs targeting Endotoxemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndotoxemiaRecruiting

ConcentrationCompleted

FunctionCompleted

EndotoxemiaPreclinical

Recruiting

ConcentrationPreclinical

Completed

FunctionPreclinical

Completed

Competition

Competitive Landscape

55 competitors in Function

#DrugCompanyPhaseTrials

Indocin

CCosette Pharmaceuticals, Inc.

Approved

3 2

Flomax

Sanofi

Phase 3

1 3

Taxol

Teva

Phase 2

1 4

N-Acetyl Cyteien

SStanford University

Phase 3

2 5

Ezallor Sprinkle

AstraZeneca

Phase 2

1 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 7

Xeljanz

PPrism Pharmaceuticals

Phase 2

1 8

Paraplatin

AAvyxa

Phase 2

1 9

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 10

Golytely

Bayer

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Inflammation

NCT06620679

Q1 2027

PreclinicalRecruiting

Endotoxemia

NCT07713641

Clinical

Trials by Indication[1]

Depression3 trials

Lipopolysaccharide (LPS) Challenge in Depression

Completed·LLaureate Institute for Brain Research, Inc.·Phase 1·NCT03142919·64 enrolled

Theophylline for Depression Study

Withdrawn·UUniversity of California, Los Angeles·Phase 1·NCT04309877

Leucine for Depression Study (L-DEP)

Terminated·UUniversity of California, Los Angeles·Phase 1·NCT03557684·59 enrolled

Immune Response2 trials

Neuroimmune Response to Lipopolysaccharide

Completed·YYale University·Phase 1·NCT04233593·27 enrolled

The Effects of Concentration/Meditation on the Innate Immune Response During Human Endotoxemia

Completed·RRadboud University Medical Center··NCT01352871·1 enrolled

Inflammation2 trials

Inflammation and Brain Function - Pilot Study

Completed·KKarolinska Institutet·N/A·NCT03551080·8 enrolled

Mapping the Effect of (neuro)inflammation on Stress Sensitivity in the Brain of Healthy Men

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·N/A·NCT06620679·20 enrolled

Endotoxemia2 trials

Defibrotide in the Human Endotoxemia Model --- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide

Completed·BBernd Jilma·Phase 4·NCT02876601·20 enrolled

Investigating the Role of Short-Chain Fatty Acids in Endotoxemia-Induced Inflammation and Core Executive Functioning: A Randomized, Triple-Blind, Placebo-Controlled Trial

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Preclinical·NCT07713641·56 enrolled

Concentration1 trial

Concentration/Meditation Limits Inflammation

Completed·RRadboud University Medical Center·N/A·NCT01835457·30 enrolled

8 more indications

Age1 trial

Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects

Completed· GSK logo

GSK·Phase 1·NCT03306589·12 enrolled

Immunotherapy1 trial

Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal

Completed·—·Phase 1·NCT05751837·10 enrolled

Hypoxia1 trial

Effects of Oxygen Status on Endotoxemia Induced Inflammation and Hypoxia Inducible Factor-1α

Completed·RRadboud University Medical Center·Phase 1/2·NCT01978158·30 enrolled

Function1 trial

Effect of Lipopolysaccharide on Skeletal Muscle Functions

Completed·UUniversity of Nottingham·N/A·NCT01423968·6 enrolled

Inflammatory Mediators1 trial

A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05884242·20 enrolled

Immune System1 trial

Imaging the Neuroimmune System in PTSD

Completed·YYale University·Phase 1·NCT04236986·34 enrolled

Inflammatory Response1 trial

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02211170·24 enrolled

Parkinson's Disease1 trial

Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR

Recruiting·—··NCT05205291·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Lipopolysaccharide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lipopolysaccharide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lipopolysaccharide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

Lipopolysaccharide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Depression3 trials

Immune Response2 trials

Inflammation2 trials

Endotoxemia2 trials

Concentration1 trial

Age1 trial

Immunotherapy1 trial

Hypoxia1 trial

Function1 trial

Inflammatory Mediators1 trial

Immune System1 trial

Inflammatory Response1 trial

Parkinson's Disease1 trial

References

Drug Info

Quick Facts

Related News